AstraZeneca lung cancer therapy combination shows promise in advanced study

AZN•2026-09-01

Chinese late-stage trial showed improved progression-free survival

AstraZeneca AZN.L said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.

AstraZeneca lung cancer therapy combination shows promise in advanced study

Chinese late-stage trial showed improved progression-free survival

Related News

Thermo Fisher Scientific <TMO.N> : HSBC raises target price to $690 from $660

Nasdaq trade halt continues <LGCL.O> reason not available at 03:58 AM

TotalEnergies names Emmanuelle Guégan marketing and services chief, joins executive committee

Nasdaq trade halt continues <PLTS.O> reason not available at 03:58 AM

Shell reports 5,532,145,677 total voting rights as of Aug. 28, 2026